Loading...
NPI 1598757718 · Tinley Park, IL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mufaddal Hamadeh is a hematology & oncology physician provider located in Tinley Park, Illinois. This profile covers 42 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Mufaddal Hamadeh |
| Address | 17333 La Grange Rd Ste 200 |
| City | Tinley Park |
| State | IL |
| ZIP | 60487 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | August 16, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.4M |
| Medicaid | $10.1K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
42 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 16,600 | $40 | $713.8K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 58,570 | $1 | $117.1K |
| J0897 | Injection, denosumab, 1 mg | 6,120 | $20 | $116.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 840 | $90 | $77.6K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,330 | $20 | $76.6K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 610 | $80 | $49K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 420 | $110 | $44.5K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 42,750 | $1 | $42.8K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 240 | $140 | $32.1K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 20 | $1,300 | $29.8K |
Showing 1–10 of 42
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 42 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
42 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 32 | 110 | 11,600 | $40 | $564.2K |
| J0897 | 90 | 410 | 2,520 | $20 | $90.8K |
| Q5119 | 4 | 40 | 1,970 | $20 | $50.6K |
| J0881 | 2 | 70 | 11,600 | $1 | $38.2K |
| J2506 | 11 | 70 | 320 | $80 | $32.9K |
| 78815 | 276 | 370 | 50 | $360 | $30.9K |
| J1439 | 15 | 80 | 25,500 | $1 | $30K |
| A9552 | 71 | 90 | 50 | $360 | $27.5K |
| J3490 | 40 | 140 | 50 | $210 | $19.4K |
| 96413 | 48 | 370 | 130 | $100 | $19.3K |
Showing 1–10 of 42
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 240 | $40 | $10.1K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 7,972 | 14,680 | 300 | $50 | $48.7K |
Other providers in the same ZIP code as Mufaddal Hamadeh, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Fitzsimmons Surgical Supply Inc | IL | Durable Medical Equipment & Medical Supplies | $0 | $13.5M |
| Wasif Shirazi | IL | Hematology & Oncology Physician | $2.3M | $2K |
| Hematogenix Laboratory Services, LLC | IL | Clinical Medical Laboratory | $796.6K | $832K |
| Advocate Southwest Ambulatory Surgery Center LLC | IL | Ambulatory Surgical Clinic/Center | $1.2M | $0 |
| Shadi Latta | IL | Hematology & Oncology Physician | $897.4K | $990 |
| Vasia Ahmed | IL | Hematology & Oncology Physician | $882.1K | $13.4K |
| Haider Shirazi | IL | Radiation Oncology Physician | $728.2K | $11K |
| Abdulrahman Masrani | IL | Diagnostic Radiology Physician | $581.5K | $1.4K |
| Fares Hamad | IL | Gastroenterology Physician | $236.8K | $345.3K |
| Mazen Diab | IL | Nephrology Physician | $317.1K | $88.5K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.